Medicover Genetics Editorial Team|

Scientifically checkedView our editorial guidelines
Scientifically checked

October 14, 2025 — Medicover Genetics is pleased to announce new clinical data of its proprietary circulating tumor DNA-based minimal residual disease (MRD) assay will be featured in a poster presentation at the 2025 European Society for Medical Oncology (ESMO) Congress.

The poster presents additional results from the DART (Durvalumab After chemoRadioTherapy) study, conducted by Oslo University Hospital. The study focuses on patients with unresectable stage III non-small cell lung cancer (NSCLC) undergoing chemoradiotherapy followed by durvalumab consolidation therapy. The study leverages Medicover Genetics’ ctDNA-based MRD assay, part of its liquid biopsy platform, to monitor residual disease through serial blood sampling during treatment and follow-up.

Attendees on behalf of Medicover Genetics include: Staffan Ternström, COO of Diagnostic Services, Medicover; Dr. Stefan C. Mehrle, Head of Medicover Genetics; and George Koumbaris, PhD, Scientific Director at Medicover Genetics Cyprus.

These findings further strengthen the growing body of clinical evidence supporting the utility and robustness of Medicover Genetics’ liquid biopsy MRD assay in oncology care.

The abstract (1819P) will be presented by Henrik Horndalsveen, Oslo Group, on Saturday, 18 October, from 12:00 to 12:45 in Hall 25.

For more information about the study, including the abstract, please visit

Last updated: October 7, 2026

Latest articles

All about genetics
Health and well-being
Hereditary diseases

  • VERACITY

    New-generation non-invasive prenatal screening from week 9 of pregnancy, analysing fetal cell-free DNA in maternal blood to detect selected chromosomal abnormalities with high sensitivity and specificity for early and reliable prenatal risk assessment.

  • Pharmacogenomics

    Enabling personalised treatments for safer, more effective care through genetic insights that guide optimal prescribing from the start and refine therapy when patients experience side effects or poor response.

  • ebiom+

    A comprehensive assessment of the endometrial microbiome and chronic endometritis pathogens to enhance clinical outcomes, prevent treatment delays, and support a more informed, personalised fertility care.

  • WES

    Advanced sequencing that simultaneously analyses a broad range of genes to detect the genetic basis of complex diseases, improve diagnostic accuracy, and inform recurrence risk assessment for better clinical decision-making.

Why Medicover Genetics

Leader in genetic testing with >25 years of experience in counselling and diagnostics

Comprehensive CE-IVD kit portfolio and seamless Technology Transfer solution for laboratories of any size

End-to-end clinical workflow from sample processing to sequencing analysis and reporting

CAP- and CLIA- and ISO15189 accredited, GMP- and ISO9001 and 13485 certified

Are you a patient?

Are you a physician?